A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

NCT02573324 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

691

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Gliosarcoma

Interventions

DRUG: Temozolomide
DRUG: Depatuxizumab mafodotin
RADIATION: Radiation
DRUG: Placebo for ABT-414

Sponsor

AbbVie

Collaborators

[object Object]